Cantor Fitzgerald upgraded Omeros Corp. to Overweight and reinstated a $22 price target, citing a better-than-expected launch of its drug Yartemlea. This upgrade is driven by strong revenue growth, positive physician feedback, and favorable reimbursement developments, suggesting a significant upside for the company.
Cantor Fitzgerald upgraded Omeros Corp. (OMER) from Neutral to Overweight and reinstated a $22 price target, indicating a strong belief in the future performance of the company's drug, Yartemlea. This upgrade is a direct result of Yartemlea's better-than-expected launch, evidenced by $28.5 million in Q2 net revenue, an 11% sequential increase. Key catalysts include the recent J-code and NTAP status, which will improve reimbursement and patient access, and positive physician feedback supporting a 30-40% long-term market share. This news presents a significant opportunity for OMER investors, as the analyst believes the market is not fully valuing Yartemlea's potential, with peak sales forecasts now at $400 million, far exceeding the company's current market cap. The short-term implication is a potential surge in stock price, while the long-term implication is sustained growth driven by Yartemlea's market penetration.